logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Jianya Zhou

zhejiang university
H指数:22
被引数:1,948

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance

雷公藤内酯醇通过抑制DCTPP1介导的细胞固有耐药性，增强癌细胞对核苷类DNA甲基转移酶抑制剂的敏感性

Nature Communications
IF15.7
2026-08-260
OA
Jianyong Liu; Qing-Li He; Jianya Zhou; Ajay M. Vaghasia; Roshan Chikarmane; Glenn Hauk; Archana Rachakonda; Nicole Castagna; Ruchama C. Steinberg; Minh-Tam Pham; Jordan M. Gregg; Alok Mishra; Yuhan Yang; Talha Anwar; Roy Elias; Pengshan Li; Jasmine Yun-Tong Kung; Anthony C. O’Donnell; Nicole M. Anders; Teresia M. Wanjiku; Philipp Nuhn; Joong Sup Shim; Hugh Giovinazzo; David M. Esopi; Kunhwa Kim; Jonathan Coulter; Rulin Wang; Jianying Zhou; Michelle A. Rudek; Kathleen Gabrielson; Angelo M. De Marzo; James M. Berger; Jun O. Liu; William G. Nelson; Srinivasan Yegnasubramanian
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer

EGFR突变型早期可切除非小细胞肺癌中分子残留病灶检测的临床应用

Nature Communications
IF15.7
2026-08-100
OA
Fei Zhou; Chunxia Su; Wenhua Liang; Li-Di Xu; Wei Tao; Juanjuan Qian; Shidong Xu; Dan Liu; Rui Fan; Yaxi Zhang; Yiqian Liu; Lin Wu; Xiangning Fu; Xiaodong Zhang; Ning Shen; Di Ge; Qun Chen; Weimin Mao; Lin Xu; Chun Chen; Bing Hu; Guoguang Shao; Jian Hu; Jian Zhao; Xiaoqing Liu; Zhidong Liu; Zheng Wang; Zemin Xiao; Taiqian Gong; Wen Lin; Xingya Li; Feng Ye; Yang Liu; Haitao Ma; Yunchao Huang; Jianying Zhou; Zhonglin Wang; Junke Fu; Lieming Ding; Li Mao; Weizhi Chen; Jianxing He; Caicun Zhou
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH)

奥希替尼作为一线治疗在中国表皮生长因子受体突变阳性晚期非小细胞肺癌患者中的有效性和安全性：一项前瞻性、多中心、非干预性研究（FLOURISH）

Cancer Biology & Medicine
IF8.4
2026-05-010
PRE
Shen, Lisha; Lv, Dongqing; Tang, Ke-Jing; Zhao, Jun; Zhu, Dan; Zhao, Yanqiu; Wang, Ke; Wang, Yan; Cai, Zhigang; Xing, Ligang; Xie, Ke; Cui, Jiuwei; Mu, Lin; Cao, Chao; Ding, Liren; Chen, Peifeng; Liang, Jun; Ding, Yongmin; Lu, Liqin; Zhang, Jiliang; Yu, Xinmin; Chen, Li; Zheng, Jing; Zhou, Jianya; Zhou, Jianying
International Consensus on Severe Lung Cancer-The Second Edition

国际重症肺癌共识（第二版）

Translational Lung Cancer Research
IF3.5
2026-04-300
PRE
Lin, Xinqing; Chu, Qian; Dong, Yuchao; Li, Min; Lv, Tangfeng; Lin, Gen; Sang, Ling; Tian, Panwen; Xia, Yang; Xie, Zhanhong; Chen, Haiming; Hong, Cheng; Jiang, Juan; Jin, Haoru; Kuai, Zhongkai; Liu, Ming; Luo, Weizhan; Luo, Yongbei; Miao, Qian; Mo, Wei; Pu, Dan; Qiu, Yuan; Qian, Zhe; Sun, Jiancong; Shi, Hui; Sun, Qinying; Sun, Yutao; Yu, Zihui; Xie, Xiaohong; Xu, Wanting; Yi, Minxiao; Yuan, Dongmei; Zhang, Longfeng; Zhao, Fei; Zhong, Changhao; Zhan, Ping; Zheng, Xiaobin; Bai, Cunxue; Chen, Enguo; Chen, Rui; Chen, Xin; Cheng, Yuan; Chen, Quanfang; Cai, Linbo; Cai, Xiuyu; Chen, Liangan; Chen, Yan; Dong, Wen; Deng, Haiyi; Fang, Wenfeng; Gan, Xin; Hao, Yue; Hu, Weidong; He, Yong; Hu, Yi; Hu, Jie; Han, Baohui; Hu, Chengping; Hu, Minjuan; Jiang, Yongliang; Jin, Yang; Liu, Dan; Liu, Weiting; Li, Wen; Li, Jing; Liu, Laiyu; Liu, Jun; Li, Weifeng; Liang, Wenhua; Lin, Jie; Liu, Hongbing; Li, Ziming; Li, Weimin; Lu, NiHong; Lu, Shun; Mu, Chuanyong; Ma, Hongxia; Miao, Liyun; Mu, Xinlin; Pu, Xingxiang; Peng, Jing; Peng, Hongbing; Qin, Jianwen; Qin, Yinyin; Ren, Shengxiang; Sun, Longhua; Su, Chunxia; Song, Yong; Tan, Xiaowu; Tang, Kejing; Tang, Xiaomei; Tong, Jianlin; Wang, Wenxian; Wu, Di; Wu, Lin; Wang, Mengzhao; Wang, Huijuan; Wang, Yuehong; Wang, Hongmei; Wang, Qi; Wang, Zhijie; Wang, Jie; Wang, Kai; Wang, Fei; Xu, Chunwei; Xie, Min; Xu, Aiguo; Xiao, Kui; Xu, Xin; Xu, Fei; Ye, Xianwei; Yang, Meng; Yang, Boyan; Ye, Xiaoqun; Ye, Feng; Yu, Zongyang; Yue, Dongsheng; Zhang, Qichuan; Zou, Juntao; Zhang, Jian; Zhuang, Li; Zhou, Jianying; Zhou, Jianya; Zhang, Bicheng; Zhang, Jian; Zhang, Jianqing; Zhang, Xiaoju; Zhao, Wei; Zhu, Bo; Zhu, Zhengfei; Zhong, Wenzhao; Zhou, Caicun; Zhou, Yanbin; He, Jianxing; Zhong, Nanshan; Saito, Yuichi; Watanabe, Satoshi; Petrella, Francesco; Nakada, Takeo; Goto, Taichiro; Fiorelli, Alfonso; Solli, Piergiorgio; Berardi, Rossana; Ichiki, Yoshinobu; Braun, Marcin; Nagasaka, Misako; Chouaid, Christos; Thawani, Rajat; Santa-Catalina, Pedro Gonzalez; Styrvoky, Kim; Abbar, Baptiste; Provencio, Mariano; Li, Shiyue; Chen, Rongchang; Zhou, Chengzhi
Andamertinib in Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results from the Phase 2 KANNON Study

安达曲尼布在EGFR外显子20插入的晚期非小细胞肺癌患者中的应用：铂类为基础的化疗或免疫治疗后的KANNON II期研究结果

Journal of Thoracic Oncology
IF20.8
2025-11-150
OAAI
Jin-Ji Yang; Yu Mu; Zhe-Hai Wang; Jian-Chun Duan; Yan Zhang; Lin Wu; Hua Zhong; Jun Zhao; Yu Yao; Ping Wang; Xiao-Ling Li; Run-Xiang Yang; Xu-Hong Min; Dong-Qing Lv; Hai-Peng Xu; Zhen-Ming Fu; Bo Shen; Long-Hua Sun; Chang-Li Wang; Jian-Ya Zhou
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

Ivonescimab 联合化疗与 tislelizumab 联合化疗作为晚期鳞状非小细胞肺癌的一线治疗（HARMONi-6）：一项随机、双盲、Ⅲ期临床试验

The Lancet
IF97.3
2025-10-190
PRE
Zhiwei Chen; Fang Yang; Zhou Jiang; Longhua Sun; Lin Wu; Zhengxiang Han; Yun Fan; Yanqiu Zhao; Xingya Li; Haipeng Xu; Xiangjiao Meng; Ying Liu; Zhiye Zhang; Hui Luo; Xuelei Ma; Xuezhen Ma; Qin Shi; Zhongmin Zhang; Runxiang Yang; Pingli Wang; Pinhua Pan; Xiaohong Ai; Jie Li; Xingxiang Pu; Zhiwu Wang; Jian Fang; Ming He; Yong He; Shuliang Guo; Juan Li; Hongbiao Wang; Junqiang Zhang; Qian Chu; Xuewen Liu; Shenpeng Ying; Hongcheng Wu; Hongmei Sun; Yinghua Ji; Ming Zhou; Chao Cao; Kejing Tang; Zhengguo Li; Dairong Li; Zhihong Zhang; Jie Li; Jianya Zhou; Hongzhong Yang; Yingying Du; Hui Yang; Jian Shi; Hualin Chen; Wenting Li; Dongmei Lu; Mingxiu Hu; Zhongmin Maxwell Wang; Baiyong Li; Michelle Xia; Shun Lu
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer

GLORY研究长期随访结果：gumarontinib在MET外显子14跳跃突变的东亚非小细胞肺癌患者中的II期研究

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-09-300
PRE
Lu, Shun; Yu, Yongfeng; Zhou, Jianya; Li, Xingya; Goto, Koichi; Min, Xuhong; Nishino, Kazumi; Cui, Jiuwei; Wu, Ling; Sakakibara, Jun; Shu, Yongqian; Dong, Xiaorong; Li, Lu; Yoneshima, Yasuto; Zhou, Chengzhi; Li, Xiaoling; Zhang, Yiping; Huang, Dingzhi; Zang, Aimin; Zhang, Wei; Wang, Xiuwen; Zhang, Li; Bai, Chong; Fang, Jian; Cao, Lejie; Zhao, Yanqiu; Yu, Yan; Shi, Meiqi; Zhong, Diansheng; Li, Fugen; Duanmu, Wenhao; Wang, Yibin
Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study

接受帕博利珠单抗治疗的非小细胞肺癌患者免疫相关内分泌毒性的危险因素及其对患者预后的影响：一项多中心回顾性研究

BMC PULMONARY MEDICINE
IF2.8
2025-03-130
OA
Zhang, Haoting; Zheng, Jing; Ren, Chenyi; Ye, Chenlin; Wu, Xiaoyu; Lv, Xiaodong; Li, Yuping; Zhou, Jianya; Zhou, Jianying
Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis

Ivacaftor是一种CFTR增效剂，通过调节cftr-pten-akt轴与osimertinib协同对抗NSCLC中对osimertinib的获得性耐药

ACTA PHARMACOLOGICA SINICA
IF8.4
2024-12-030
PRE
Li, Yue-kang; Ge, Fu-jing; Liu, Xiang-ning; Zeng, Chen-ming; Qian, Mei-jia; Li, Yong-hao; Zheng, Ming-ming; Qu, Jing-jing; Fang, Liang-jie; Lu, Jin-jian; Yang, Bo; He, Qiao-jun; Zhou, Jian-ya; Zhu, Hong
Real-world effectiveness and safety of fi rst-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study)

真实世界中EGFR突变（EGFRm）晚期非小细胞肺癌（NSCLC）患者一线（1L）奥希替尼的有效性与安全性：一项在中国进行的前瞻性、多中心、真实世界研究（FLOURISH研究）

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Zhou, J.; Shen, L.; Lv, D.; Tang, K.; Zhu, D.; Zhao, Y.; Wang, K.; Wang, Y.; Xing, L.; Cui, J.; Ding, L.; Shi, X.; Zheng, J.
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial

Ivonescimab联合化疗治疗EGFR变异的非小细胞肺癌随机临床试验

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
IF55
2024-08-209
OA
Fang, Wenfeng; Zhao, Yuanyuan; Luo, Yongzhong; Yang, Runxiang; Huang, Yan; He, Zhiyong; Zhao, Hui; Li, Mingjun; Li, Kai; Song, Qibing; Du, Xiaobo; Sun, Yulan; Li, Wei; Xu, Fei; Wang, Zhiyu; Yang, Kunning; Fan, Yun; Liu, Baogang; Zhao, Hongyun; Hu, Ying; Jia, Li; Xu, Shen; Yi, Tienan; Lv, Dongqing; Lan, Haitao; Li, Mengxia; Liang, Wenhua; Wang, Yongsheng; Yang, Hui; Jia, Yuming; Chen, Yuan; Lu, Junguo; Feng, Jifeng; Liu, Chunling; Zhou, Ming; Zhou, Jianya; Liu, Xianling; Zhou, Ningning; He, Ming; Dong, Xiaorong; Chen, Hualin; Chen, Yongxing; Su, Haichuan; Li, Xiaoling; Zhang, Zhihong; Yang, Lei; Cheng, Ying; Chen, Likun; Hou, Xue; Zhang, Yu; Guo, Jun; Wang, Zhen; Lu, Hong; Wu, Di; Feng, Weineng; Li, Wen; Huang, Jianan; Wang, Yan; Song, Xia; Peng, Jiewen; Liu, Laiyu; Guo, Yubiao; Li, Wenting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Zhang, Li
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China

人类表皮生长因子受体2抗体-药物偶联物诱导的间质性肺疾病/肺炎跨学科管理的临床最佳实践: 中国专家共识

CANCER
IF5.1
2024-08-021
PRE
Xu, Chunwei; Chen, Zhanhong; Xia, Yuanli; Shi, Yanxia; Fu, Peifen; Chen, Yiding; Wang, Xian; Zhang, Lili; Li, Hengyu; Chen, Wenyan; Fu, Jianfei; Huang, Liming; Shu, Jingde; Wang, Ouchen; Wu, Weizhu; Xie, Bojian; Wang, Ting; Zhang, Weiping; Shen, Shurong; Li, Qun; Luo, Ting; Zhang, Bin; Xie, Yanru; Wang, Hongxia; Wang, Qian; Wang, Wenxian; Li, Ziming; Song, Zhengbo; Fang, Wenfeng; Zhong, Wenzhao; Zhang, Yongchang; Zhan, Ping; Liu, Hongbing; Lv, Tangfeng; Miao, Liyun; Min, Lingfeng; Wang, Feng; Meng, Rui; Zhu, Youcai; Wang, Lin; Wan, Bing; Wang, Dong; Hao, Yue; Zhou, Jianya; Huang, Long; Zhang, Zhang; Lv, Donglai; Fang, Meiyu; Lu, Yuanzhi; Si, Lu; Song, Yong; Wang, Xiaojia
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2024-07-310
OAAI
Yu, Yongfeng; Dong, Wen; Shi, Yanxia; Wu, Rong; Yu, Qitao; Ye, Feng; Zhou, Chengzhi; Dong, Xiaorong; Li, Xingya; Li, Yongsheng; Li, Zhen; Wu, Lin; Pan, Yueyin; Shen, Hong; Wu, Dehua; Xu, Zhongyuan; Wu, Jinsheng; Xu, Nong; Qin, Yanru; Zang, Aimin; Zhang, Jingdong; Zhou, Jianya; Zhang, Xiaotao; Zhao, Yanqiu; Wang, Huizhen; Li, Fugen; Liu, Qi; Han, Zhenyong; Li, Jin; Lu, Shun

研究方向

暂未获取到该数据
J
Jianying Zhou
H 指数:66论文数:860被引数:2.4万
J
Jing Zheng
H 指数:30论文数:175被引数:3,117
Y
Yanqiu Zhao
H 指数:32论文数:212被引数:6,818
W
Wenjia Sun
H 指数:20论文数:86被引数:1,257
陆
陆舜
H 指数:78论文数:904被引数:3.6万
J
Jingjing Qu
H 指数:21论文数:107被引数:2,499
D
Dongqing Lv
H 指数:25论文数:191被引数:2,646
J
Jian Fang
H 指数:35论文数:247被引数:6,355
L
Lejie Cao
H 指数:23论文数:91被引数:2,715
K
Kexin Ruan
H 指数:6论文数:17被引数:76